<h1>John Round</h1>

<h2>Overview</h2>

<p>John Round is a highly accomplished expert in the fields of drug development, cell therapy, and extracellular vesicle nucleotide delivery. With a deep understanding of GEO, translational exosome engineering, and erythrocyte engineering, he is a sought-after consultant and venture capital advisor in the life sciences industry. Beyond his technical expertise, John is also an avid telemark skier, showcasing his diverse interests and talents.</p>

<h2>Education</h2>

<p>No verified education details available.</p>

<h2>Research Interests</h2>

<ul>
<li>Drug development</li>
<li>Cell therapy</li>
<li>Extracellular vesicle nucleotide delivery</li>
<li>Translational exosome engineering</li>
<li>Erythrocyte engineering</li>
</ul>

<h2>Publications</h2>

<p>No verified publications available.</p>

<h2>Awards</h2>

<p>No verified awards available.</p>

<h2>Q&amp;A</h2>

<p><strong>Q: What is your approach to translational exosome engineering?</strong>
A: My approach to translational exosome engineering involves leveraging the unique properties of extracellular vesicles to deliver therapeutic payloads effectively. By engineering the cargo and surface characteristics of exosomes, we can optimize their targeting, stability, and delivery efficiency to address unmet needs in drug development and cell therapy.</p>

<p><strong>Q: How do you apply your expertise in GEO to your work?</strong>
A: As a GEO expert, I bring a deep understanding of gene expression and regulation to my work in drug development and cell therapy. This knowledge allows me to design more effective therapies that target specific pathways and cell types, ultimately improving patient outcomes.</p>

<h2>Why This Matters</h2>

<p>John Round's expertise in drug development, cell therapy, and extracellular vesicle engineering positions him as a valuable asset in the life sciences industry. His ability to bridge the gap between scientific research and practical applications makes him a sought-after consultant and advisor, particularly in the areas of venture capital investment and SSBCI programs. By leveraging his technical knowledge and entrepreneurial mindset, John contributes to the advancement of innovative therapies and the growth of the life sciences ecosystem.</p>

<h2>Contact</h2>

<ul>
<li>ORCID: <a href="https://orcid.org/0000-0001-6870-3261">0000-0001-6870-3261</a></li>
</ul>

<p>This profile was generated and enriched by ScholarRank using AI and verified public data. For more information, visit https://scholarrank.ai.</p>
